Role of platelet rich plasma in management of compound fractures

A Randomized control trial to study the role of platelet rich plasma in management of compound fractures - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056367

Enrollment

Registered

2023-08-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: -

Interventions

Intervention1: Platelet rich plasma: Platelet rich plasma is a centrifuged fraction of plasma that is a thrombocyte concentrate. It is an autologous source of cellular Growth factors that aids in and

Eligibility

Inclusion criteria

Inclusion criteria: All patients with compound fractures of tibia and fibula or isolated tibia

Exclusion criteria

Exclusion criteria: - Co morbid conditions like sickle cell anaemia , blood dyscrasias. - Tibia and fibula fractures associated with femur fracture - Tibia and fibula fractures with associated knee injuries - Tibia and fibula fractures with other upper limb long bone fractures

Design outcomes

Primary

Measure	Time frame
Platelet rich plasma will facilitate faster wound healing.Timepoint: Pictures of wound taken on every 4th day	—

Secondary

Measure	Time frame
Fracture healing with PRPTimepoint: Serial x rays taken at 3 , 6 , 12 weeks	—

Countries

India

Contacts

Public ContactDr Prathamesh kale

DATTA MEGHE INSTITUTE OF HIGHER EDUCATION AND RESEARCH

drsandeepshrivastava@gmail.com9765404068

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026